A Phase 1 interventional study of QY101 ointment or vehicle in Healthy Volunteer, sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-25.
Sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase I, randomized, double-blind, vehicle-controlled,single and multiple ascending dose study to assess the safety, tolerability, and pharmacokinetics of QY101 ointment in Chinese healthy subjects
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 subjects use 0.1% QY101 ointment,1 subject uses vehicle topical applied to 5% Body Surface Area,assessed until 72 hours postdose
Drug: QY101 ointment or vehicle
6 subjects use 0.1% QY101 ointment,2 subjects use vehicle topical applied to 20% Body Surface Area,assessed until 72 hours postdose
Drug: QY101 ointment or vehicle
6 subjects use 0.3% QY101 ointment,2 subjects use vehicle topical applied to 20% Body Surface Area,assessed until 72 hours postdose
Drug: QY101 ointment or vehicle
6 subjects use 0.5% QY101 ointment,2 subjects use vehicle topical applied to 20% Body Surface Area,assessed until 72 hours postdose
Drug: QY101 ointment or vehicle
6 subjects use 1.0% QY101 ointment,2 subjects use vehicle topical applied to 20% Body Surface Area,assessed until 72 hours postdose
Drug: QY101 ointment or vehicle
6 subjects use 1.0% QY101 ointment,2 subjects use vehicle topical applied to 40% Body Surface Area,assessed until 72 hours postdose
Drug: QY101 ointment or vehicle
6 subjects use 0.3% QY101 ointment,2 subjects use vehicle topical applied to 20% Body Surface Area,twice daily for 7 days and once in the morning on D8
Drug: QY101 ointment or vehicle
6 subjects use 0.5% QY101 ointment,2 subjects use vehicle topical applied to 20% Body Surface Area,twice daily for 7 days and once in the morning on D8
Drug: QY101 ointment or vehicle
6 subjects use 1.0% QY101 ointment,2 subjects use vehicle topical applied to 20% Body Surface Area,twice daily for 7 days and once in the morning on D8
Drug: QY101 ointment or vehicle
6 subjects use 1.0% QY101 ointment,2 subjects use vehicle topical applied to 40% Body Surface Area,twice daily for 7 days and once in the morning on D8
Drug: QY101 ointment or vehicle
QY101 ointment or vehicl topical applied to skin
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: SAD:Day1 to Day18;MAD:Day1 to Day25
Number of Participants With Clinical Laboratory Abnormalities
Time frame: SAD:Screening period and Day4;MAD:Screening period, Day5 and Day11
Number of Participants With Clinically Significant Changes Form Baseline in Vital Signs
Time frame: SAD:Screening period and Day1 to Day4;MAD:Screening period and Day1 to Day11
Severity of local skin irritation
Skin irritation response assessment recording method: -: no reaction; + (mild): only erythema can be observed; + (moderate): moderate erythema, edema; + (severe): severe erythema, edema with papules, vesicles; + (severe): severe erythema, edema, bullae, and even necrosis.
Time frame: SAD:Day1 to Day4;MAD:Day1 to Day11
Number of Participants With Clinically Significant Treatment-emergent Electrocardiogram (ECG) Findings
Time frame: SAD:Screening period and Day4;MAD:Screening period, Day5 and Day11
Number of Participants With Clinically Significant Changes Form Baseline in Physical Examination
Time frame: SAD:Screening period and Day4;MAD:Screening period, Day5 and Day11
Tmax of QY101
Time of maximum concentration
Time frame: SAD:Day1 to Day4;MAD:Day1,Day5 to Day11
Cmax of QY101
Maximum observed plasma concentration
Time frame: SAD:Day1 to Day4;MAD:Day1,Day5 to Day11
t1/2 of QY101
The time it takes for the blood concentration of the drug to drop by half from the highest value in the body
Time frame: SAD:Day1 to Day4;MAD:Day1,Day5 to Day11
AUC0-∞ of QY101
Area under the plasma concentration-time curve from time zero to the last quantifiable concentration
Time frame: SAD:Day1 to Day4;MAD:Day1,Day5 to Day11
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2022 to primary completion in Jun 2023, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.